![Martin Stogniew](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Martin Stogniew
Corporate Officer/Principal bei Oncoceutics, Inc.
Aktive Positionen von Martin Stogniew
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Oncoceutics, Inc.
![]() Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01.01.2012 | - |
Direktor/Vorstandsmitglied | 01.01.2012 | - |
Karriereverlauf von Martin Stogniew
Ehemalige bekannte Positionen von Martin Stogniew
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 19.07.2011 | - |
Vicuron Pharmaceuticals LLC
![]() Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2001 | - |
Ausbildung von Martin Stogniew
University of Maryland | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Vicuron Pharmaceuticals LLC
![]() Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
Ceptaris Therapeutics, Inc.
![]() Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Oncoceutics, Inc.
![]() Oncoceutics, Inc. Pharmaceuticals: MajorHealth Technology Oncoceutics, Inc. operates as a clinical-stage biopharmaceutical company. It is a drug discovery and development company targeting the most potent suppressor pathways in human cancer. The firm develops technology and therapies including ONC201, for natural potent tumor suppressor pathways in human cancer. Oncoceutics was founded by Wafik El-Deiry, Wolfgang Oster and Lee T. Schalop in 2009 and is headquartered in Philadelphia, PA. | Health Technology |
- Börse
- Insiders
- Martin Stogniew
- Erfahrung